688389 普门科技
已收盘 11-16 15:00:00
资讯
新帖
简况
普门科技全球研发智造基地项目顺利封顶!
同花顺 · 16:07
普门科技全球研发智造基地项目顺利封顶!
【机构调研记录】融通基金调研普门科技
证券之星 · 08:02
【机构调研记录】融通基金调研普门科技
【机构调研记录】交银施罗德基金调研珠城科技、普门科技
证券之星 · 08:01
【机构调研记录】交银施罗德基金调研珠城科技、普门科技
普门科技:11月10日接受机构调研,华泰证券股份有限公司、长江证券股份有限公司等多家机构参与
证券之星 · 11-13 19:10
普门科技:11月10日接受机构调研,华泰证券股份有限公司、长江证券股份有限公司等多家机构参与
股市必读:普门科技(688389)11月6日披露最新机构调研信息
证券之星 · 11-09
股市必读:普门科技(688389)11月6日披露最新机构调研信息
普门科技:11月5日接受机构调研,深圳光影资本管理有限公司、深圳市徐星私募证券基金管理有限公司等多家机构参与
证券之星 · 11-06
普门科技:11月5日接受机构调研,深圳光影资本管理有限公司、深圳市徐星私募证券基金管理有限公司等多家机构参与
普门科技:10月30日召开业绩说明会,Enreal Asset Management Limited、德邦基金管理有限公司等多家机构参与
证券之星 · 11-03
普门科技:10月30日召开业绩说明会,Enreal Asset Management Limited、德邦基金管理有限公司等多家机构参与
股市必读:普门科技三季报 - 第三季度单季净利润同比下降15.13%
证券之星 · 11-02
股市必读:普门科技三季报 - 第三季度单季净利润同比下降15.13%
普门科技(688389)9月30日股东户数1.15万户,较上期增加5.18%
证券之星 · 10-30
普门科技(688389)9月30日股东户数1.15万户,较上期增加5.18%
图解普门科技三季报:第三季度单季净利润同比下降15.13%
证券之星 · 10-30
图解普门科技三季报:第三季度单季净利润同比下降15.13%
普门科技(688389)10月26日主力资金净买入800.25万元
证券之星 · 10-27
普门科技(688389)10月26日主力资金净买入800.25万元
普门科技涨8.10%,东海证券一个月前给出“买入”评级
证券之星 · 10-26
普门科技涨8.10%,东海证券一个月前给出“买入”评级
普门科技(688389)10月22日主力资金净买入3.34万元
证券之星 · 10-23
普门科技(688389)10月22日主力资金净买入3.34万元
股市必读:普门科技新发布《深圳普门科技股份有限公司关于自愿披露公司产品获得美国FDA 510(k)准入的公告》
证券之星 · 10-12
股市必读:普门科技新发布《深圳普门科技股份有限公司关于自愿披露公司产品获得美国FDA 510(k)准入的公告》
普门科技(688389)披露公司产品获得美国FDA 510(k)准入,10月09日股价下跌0.44%
证券之星 · 10-09
普门科技(688389)披露公司产品获得美国FDA 510(k)准入,10月09日股价下跌0.44%
普门科技最新公告:H100Plus血红蛋白检测系统获美国FDA510(k)准入
证券之星 · 10-08
普门科技最新公告:H100Plus血红蛋白检测系统获美国FDA510(k)准入
普门科技:控股子公司取得光子治疗仪医疗器械注册证
格隆汇 · 09-29
普门科技:控股子公司取得光子治疗仪医疗器械注册证
普门科技(688389)披露公司产品获得欧盟MDR认证,9月22日股价上涨1.09%
证券之星 · 09-22
普门科技(688389)披露公司产品获得欧盟MDR认证,9月22日股价上涨1.09%
普门科技:电化学发光物质已实现自研自产
证券之星 · 09-16
普门科技:电化学发光物质已实现自研自产
普门科技:采用多产品、多市场平台型发展模式
证券之星 · 09-16
普门科技:采用多产品、多市场平台型发展模式
加载更多
公司概况
公司名称:
深圳普门科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2019-11-05
主营业务:
深圳普门科技股份有限公司的主营业务是医疗器械的研发、制造、营销及服务。公司的主要产品是光子治疗仪、红外治疗仪、空气波压力治疗系统、高频振动排痰系统、特定蛋白分析仪、糖化血红蛋白分析仪、电化学发光免疫分析仪、配套检测试剂。公司的“特定蛋白分析仪产业化项目”获得“2018年度深圳市科技进步奖一等奖”,系列产品已获国内顶级医院认可。
发行价格:
9.10
{"stockData":{"symbol":"688389","market":"SH","secType":"STK","nameCN":"普门科技","latestPrice":11.16,"timestamp":1794812400000,"preClose":11.12,"halted":0,"volume":1856773,"delay":0,"changeRate":0.0036,"floatShares":428000000,"shares":428000000,"eps":0.3166,"marketStatus":"已收盘","change":0.04,"latestTime":"11-16 15:00:00","open":11.34,"high":11.35,"low":11.02,"amount":20736100,"amplitude":0.0297,"askPrice":11.16,"askSize":84,"bidPrice":11.12,"bidSize":234,"shortable":0,"etf":0,"ttmEps":0.3166,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794879000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.12,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794792600000,1794799800000],[1794805200000,1794812400000]],"highLimit":12.23,"lowLimit":10.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":428485730,"isCdr":false,"pbRate":2.27,"roa":"--","peRate":35.249526,"roe":"5.39%","epsLYR":0.43,"committee":0.608741,"marketValue":4782000000,"turnoverRate":0.0043,"status":0,"afterMarket":{"amount":0,"volume":0,"close":11.16,"buyVolume":1000,"sellVolume":0,"time":1794814437746,"indexStatus":"已收盘 11-16 15:30:00","preClose":11.12},"floatMarketCap":4782000000},"requestUrl":"/m/hq/s/688389","defaultTab":"news","newsList":[{"id":"2683699456","title":"普门科技全球研发智造基地项目顺利封顶!","url":"https://stock-news.laohu8.com/highlight/detail?id=2683699456","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683699456?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:07","pubTimestamp":1794816420,"startTime":"0","endTime":"0","summary":"11月12日,普门科技全球研发智造基地项目(松山湖产业园区二期项目)主体结构封顶仪式在东莞松山湖隆重举行。松山湖管委会机关领导,公司管理层代表,以及项目施工单位、监理单位、设计单位代 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261116/c681857744.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261116/c681857744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688389","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683666349","title":"【机构调研记录】融通基金调研普门科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2683666349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683666349?lang=zh_cn&edition=full","pubTime":"2026-11-16 08:02","pubTimestamp":1794787356,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月13日披露的机构调研信息,融通基金近期对1家上市公司进行了调研,相关名单如下:1)普门科技 调研纪要:随着公司发光系列仪器及配套试剂产品的持续丰富与完善,公司发光产品的市场竞争力正稳步增强。融通基金成立于2001年,截至目前,资产管理规模1453.73亿元;资产管理规模675.98亿元;管理公募基金数197只;旗下公募基金经理42人。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600002007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683663407","title":"【机构调研记录】交银施罗德基金调研珠城科技、普门科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2683663407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683663407?lang=zh_cn&edition=full","pubTime":"2026-11-16 08:01","pubTimestamp":1794787279,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月13日披露的机构调研信息,交银施罗德基金近期对2家上市公司进行了调研,相关名单如下:1)珠城科技 调研纪要:公司立足家电连接器,拓展至通讯、汽车、新能源、工业等领域,打造成为连接器行业精密制造的标杆企业。交银施罗德基金成立于2005年,截至目前,资产管理规模5742.6亿元;资产管理规模2352.48亿元;管理公募基金数297只;旗下公募基金经理48人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600001938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","688389","301280","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683572685","title":"普门科技:11月10日接受机构调研,华泰证券股份有限公司、长江证券股份有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2683572685","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683572685?lang=zh_cn&edition=full","pubTime":"2026-11-13 19:10","pubTimestamp":1794568252,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年11月13日普门科技发布公告称公司于2026年11月10日接受机构调研,华泰证券股份有限公司、长江证券股份有限公司、中银基金管理有限公司、上海东方证券资产管理有限公司、富国基金管理有限公司、交银施罗德基金管理有限公司、平安资产管理有限责任公司、兴证全球基金管理有限公司、融通基金管理有限公司、广发基金管理有限公司参与。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300036300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","BK0188","LU0871576103.HKD","LU0531971595.HKD","LU1979443071.USD","LU1808992512.USD","LU0164865239.USD","LU1064131003.USD","688389","LU0039217434.USD","BK0201","LU1781817850.SGD","BK0183","BK0251","LU2148510915.USD","601688","BK0012","LU1328615791.USD","LU1064130708.USD","LU1580142542.USD","BK0276","BK0028","000783"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682829983","title":"股市必读:普门科技(688389)11月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2682829983","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682829983?lang=zh_cn&edition=full","pubTime":"2026-11-09 05:16","pubTimestamp":1794172575,"startTime":"0","endTime":"0","summary":"截至2026年11月6日收盘,普门科技报收于11.66元,下跌2.26%,换手率0.66%,成交量2.83万手,成交额3323.02万元。机构调研要点11月5日特定对象调研,现场参观皮肤医美业务收入主要来源于国内市场,核心产品为超声皮肤治疗仪;半导体激光脱毛仪已获得美国FDA 510认证,国际医美业务处于渠道开发阶段;国内医美行业进入整合期,差异化能量源技术产品更受机构青睐。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900001524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681898566","title":"普门科技:11月5日接受机构调研,深圳光影资本管理有限公司、深圳市徐星私募证券基金管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2681898566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681898566?lang=zh_cn&edition=full","pubTime":"2026-11-06 23:24","pubTimestamp":1793978695,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年11月6日普门科技发布公告称公司于2026年11月5日接受机构调研,深圳光影资本管理有限公司、深圳市徐星私募证券基金管理有限公司、嘉兴青蒿投资有限公司、深圳市嘉亿资产管理有限公司、东方财富证券股份有限公司、国联基金管理有限公司、长江证券股份有限公司、汇丰晋信基金管理有限公司参与。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600037750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161720","688389","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680721225","title":"普门科技:10月30日召开业绩说明会,Enreal Asset Management Limited、德邦基金管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2680721225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680721225?lang=zh_cn&edition=full","pubTime":"2026-11-03 21:14","pubTimestamp":1793711658,"startTime":"0","endTime":"0","summary":"从执行层面来看,指南将开启全国分阶段落地,全国划分为四个价区,并指定六个省份作为试点先行。今年前三季度,医美业务在超声产品的带动下,实现大幅增长。射频技术平台产品在正常研发进展中,以构建公司医美特色能量产品组合。目前该业务以居家美容和居家康复为主,未来将拓展到居家检测业务。2026年前三季度,公司整体毛利率为 62.68%,较上年同期下降 0.61 个百分点。总体而言,公司毛利率维持在合理区间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300042789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680783274","title":"股市必读:普门科技三季报 - 第三季度单季净利润同比下降15.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680783274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680783274?lang=zh_cn&edition=full","pubTime":"2026-11-02 07:58","pubTimestamp":1793577495,"startTime":"0","endTime":"0","summary":"业绩披露要点:2026年前三季度归母净利润1.14亿元,同比下降29.79%。深圳普门科技股份有限公司关于2026年前三季度计提资产减值准备的公告公司对截至2026年9月30日的资产进行减值测试,2026年前三季度合计计提信用减值损失和资产减值损失2,162.30万元,其中信用减值损失109.50万元,资产减值损失2,052.81万元;本次计提减少公司合并报表利润总额2,162.30万元,未经审计,最终以年度审计结果为准;计提符合会计准则及公司实际情况,不影响正常经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200002122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213864","title":"普门科技(688389)9月30日股东户数1.15万户,较上期增加5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213864","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213864?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:12","pubTimestamp":1793358778,"startTime":"0","endTime":"0","summary":"证券之星消息,近日普门科技披露,截至2026年9月30日公司股东户数为1.15万户,较6月30日增加567.0户,增幅为5.18%。在医疗器械行业个股中,普门科技股东户数低于行业平均水平,截至9月30日,医疗器械行业平均股东户数为2.1万户。从股价来看,2026年6月30日至2026年9月30日,普门科技区间涨幅为16.24%,在此期间股东户数增加567.0户,增幅为5.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679193287","title":"图解普门科技三季报:第三季度单季净利润同比下降15.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679193287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679193287?lang=zh_cn&edition=full","pubTime":"2026-10-30 00:58","pubTimestamp":1793293118,"startTime":"0","endTime":"0","summary":"证券之星消息,普门科技2026年三季报显示,前三季度公司主营收入9.29亿元,同比上升21.82%;归母净利润1.14亿元,同比下降29.79%;扣非净利润1.13亿元,同比下降25.92%;其中2026年第三季度,公司单季度主营收入3.25亿元,同比上升27.11%;单季度归母净利润3519.23万元,同比下降15.13%;单季度扣非净利润3645.21万元,同比下降12.97%;负债率24.63%,投资收益-155.01万元,财务费用3239.6万元,毛利率62.68%。财报数据概要请见下图:本文数据来源于普门科技2026年三季报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000002681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678211000","title":"普门科技(688389)10月26日主力资金净买入800.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678211000","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678211000?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:11","pubTimestamp":1793059919,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月26日收盘,普门科技报收于12.15元,上涨8.1%,换手率2.61%,成交量11.17万手,成交额1.33亿元。近5日资金流向一览见下表:普门科技融资融券信息显示,融资方面,当日融资买入933.45万元,融资偿还1094.64万元,融资净偿还161.19万元。普门科技主营业务:医疗器械的研发、制造、营销及服务,专注于治疗与康复设备和体外诊断设备和配套检测试剂的开发及技术创新。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700010079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678391163","title":"普门科技涨8.10%,东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678391163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678391163?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:36","pubTimestamp":1793003793,"startTime":"0","endTime":"0","summary":"今日普门科技涨8.10%,收盘报12.15元。公司国内市场企稳向好, 海外市场快速增长, 维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为38.76%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为太平洋的盛丽华。普门科技个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600021791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688389","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677918417","title":"普门科技(688389)10月22日主力资金净买入3.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677918417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677918417?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:21","pubTimestamp":1792714874,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月22日收盘,普门科技报收于11.03元,下跌0.09%,换手率0.44%,成交量1.88万手,成交额2075.27万元。近5日资金流向一览见下表:普门科技融资融券信息显示,融资方面,当日融资买入321.01万元,融资偿还430.84万元,融资净偿还109.83万元。普门科技主营业务:医疗器械的研发、制造、营销及服务,专注于治疗与康复设备和体外诊断设备和配套检测试剂的开发及技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300007468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674384908","title":"股市必读:普门科技新发布《深圳普门科技股份有限公司关于自愿披露公司产品获得美国FDA 510(k)准入的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674384908","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674384908?lang=zh_cn&edition=full","pubTime":"2026-10-12 05:43","pubTimestamp":1791754991,"startTime":"0","endTime":"0","summary":"公司公告汇总深圳普门科技股份有限公司关于自愿披露公司产品获得美国FDA 510准入的公告H100Plus血红蛋白检测系统于2026年10月2日获得美国FDA 510准入,属Class II监管类别,用于体外定量检测人全血中糖化血红蛋白含量,可辅助糖尿病诊断;获批表明产品符合美国FDA相关要求,具备进入美国市场资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674855850","title":"普门科技(688389)披露公司产品获得美国FDA 510(k)准入,10月09日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674855850","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674855850?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:29","pubTimestamp":1791541753,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘,普门科技报收于11.32元,较前一交易日下跌0.44%,最新总市值为48.5亿元。深圳普门科技股份有限公司于近日披露《关于自愿披露公司产品获得美国FDA 510准入的公告》。公告显示,其H100Plus血红蛋白检测系统已获得美国FDA 510准入,获批时间为2026年10月2日,产品属于Class II监管类别,用于体外定量检测人全血中糖化血红蛋白含量,可辅助糖尿病诊断。该产品获准表明符合美国FDA相关要求,具备进入美国市场的资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900031672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079136","title":"普门科技最新公告:H100Plus血红蛋白检测系统获美国FDA510(k)准入","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079136","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673079136?lang=zh_cn&edition=full","pubTime":"2026-10-08 19:00","pubTimestamp":1791457247,"startTime":"0","endTime":"0","summary":"普门科技(688389.SH)公告称,公司收到美国食品药品监督管理局通知,H100Plus血红蛋白检测系统获得美国FDA510(k)准入,用于体外定量检测人全血中糖化血红蛋白含量,可辅助糖尿病诊断。该产品获准进入美国市场,有利于提升公司产品开拓海外市场的综合竞争力,对公司国际业务发展具有积极作用。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800027573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297322","title":"普门科技:控股子公司取得光子治疗仪医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297322","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671297322?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:57","pubTimestamp":1790672274,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688389","BK0251","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669614806","title":"普门科技(688389)披露公司产品获得欧盟MDR认证,9月22日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669614806","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669614806?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:49","pubTimestamp":1790070556,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘,普门科技报收于11.13元,较前一交易日上涨1.09%,最新总市值为47.69亿元。近日,深圳普门科技股份有限公司发布关于自愿披露公司产品获得欧盟MDR认证的公告。公告显示,公司近期获得欧盟MDR认证证书,证书编号G15 099663 0015 Rev.00,签批时间为2026年9月16日,有效期至2028年10月16日。上述产品通过CE认证,符合欧盟最新医疗器械法规要求,具备在欧盟市场销售的准入条件,有助于推动相关产品的海外推广与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200031436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","FESXmain","FSXEmain","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667865605","title":"普门科技:电化学发光物质已实现自研自产","url":"https://stock-news.laohu8.com/highlight/detail?id=2667865605","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667865605?lang=zh_cn&edition=full","pubTime":"2026-09-16 15:34","pubTimestamp":1789544063,"startTime":"0","endTime":"0","summary":"证券之星消息,普门科技(688389)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司在近三年,诊断试剂的自产率到多少了?抗体抗原以及核心原材料目前能不能做到完全自产?谢谢!普门科技回复:在电化学发光试剂方面,核心原料电化学发光物质已实现自研自产,抗原抗体是与核心供应商合作研发;在糖化血红蛋白试剂方面,色谱填料与层析柱均已实现100%自产,质控品、校准品亦100%自产;在特定蛋白试剂方面,核心原料胶乳微球已完全实现自主生产,其他原料正在积极规划中。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600019464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605871","title":"普门科技:采用多产品、多市场平台型发展模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667605871?lang=zh_cn&edition=full","pubTime":"2026-09-16 15:34","pubTimestamp":1789544063,"startTime":"0","endTime":"0","summary":"证券之星消息,普门科技(688389)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问:今年迈瑞开始加大急诊的开发,公司是否面临较大的竞争压力?有何应对措施?谢谢!普门科技回复:尊敬的投资者,您好!公司采用多产品、多市场的平台型公司发展模式,让公司能够更好地抵御市场不确定性风险。依托多年来的技术沉淀和渠道资源积累,公司坚持在体外诊断、临床医疗、皮肤医美和消费者健康四大业务板块进行拓展,形成独特的竞争优势,可以支撑公司未来中长期的持续稳定成长。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600019466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688389"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794821923740,"stockEarnings":[{"period":"1week","weight":-0.0463},{"period":"1month","weight":0.0109},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0869},{"period":"1year","weight":-0.1947},{"period":"ytd","weight":-0.1228}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳普门科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"11522人(较上一季度增加5.18%)","perCapita":"37188股","listingDate":"2019-11-05","address":"广东省深圳市龙华区观湖街道观城社区求知东路8号普门科技总部大厦","registeredCapital":"42848万元","survey":" 深圳普门科技股份有限公司的主营业务是医疗器械的研发、制造、营销及服务。公司的主要产品是光子治疗仪、红外治疗仪、空气波压力治疗系统、高频振动排痰系统、特定蛋白分析仪、糖化血红蛋白分析仪、电化学发光免疫分析仪、配套检测试剂。公司的“特定蛋白分析仪产业化项目”获得“2018年度深圳市科技进步奖一等奖”,系列产品已获国内顶级医院认可。","listedPrice":9.1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普门科技(688389)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普门科技(688389)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普门科技,688389,普门科技股票,普门科技股票老虎,普门科技股票老虎国际,普门科技行情,普门科技股票行情,普门科技股价,普门科技股市,普门科技股票价格,普门科技股票交易,普门科技股票购买,普门科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普门科技(688389)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普门科技(688389)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}